- Home
- TRIB vs SNTI Comparison
TRIB vs SNTI Comparison
Compare TRIB & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- SNTI
- Stock Information
- Founded
- TRIB 1992
- SNTI 2016
- Country
- TRIB Ireland
- SNTI United States
- Employees
- TRIB N/A
- SNTI N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- SNTI Health Care
- Exchange
- TRIB Nasdaq
- SNTI Nasdaq
- Market Cap
- TRIB 24.0M
- SNTI 21.4M
- IPO Year
- TRIB N/A
- SNTI N/A
- Fundamental
- Price
- TRIB $0.77
- SNTI $4.57
- Analyst Decision
- TRIB
- SNTI Strong Buy
- Analyst Count
- TRIB 0
- SNTI 1
- Target Price
- TRIB N/A
- SNTI $12.00
- AVG Volume (30 Days)
- TRIB 258.9K
- SNTI 98.1K
- Earning Date
- TRIB 11-15-2024
- SNTI 03-20-2025
- Dividend Yield
- TRIB N/A
- SNTI N/A
- EPS Growth
- TRIB N/A
- SNTI N/A
- EPS
- TRIB N/A
- SNTI N/A
- Revenue
- TRIB $59,126,000.00
- SNTI N/A
- Revenue This Year
- TRIB $11.63
- SNTI $11.52
- Revenue Next Year
- TRIB $10.13
- SNTI $78.57
- P/E Ratio
- TRIB N/A
- SNTI N/A
- Revenue Growth
- TRIB N/A
- SNTI N/A
- 52 Week Low
- TRIB $0.75
- SNTI $1.52
- 52 Week High
- TRIB $3.55
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- TRIB 38.04
- SNTI 55.11
- Support Level
- TRIB $0.75
- SNTI $3.72
- Resistance Level
- TRIB $1.04
- SNTI $4.93
- Average True Range (ATR)
- TRIB 0.08
- SNTI 0.46
- MACD
- TRIB 0.01
- SNTI 0.04
- Stochastic Oscillator
- TRIB 7.83
- SNTI 74.83
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.